Skip to main content

Table 1 Distribution of main asthma comorbidities in the PROXIMA study population

From: Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis

Comorbidity

N = 123

Number of patients with at least one comorbidity

77 (62.6%)

Allergic bronchopulmonary aspergillosis

2 (1.6%)

Atopic dermatitis

3 (2.4%)

Bronchiectasis

3 (2.4%)

Cardiovascular disease

26 (21.1%)

Chronic obstructive pulmonary disease

4 (3.3%)

Chronic rhinitis

17 (13.8%)

Chronic rhinosinusitis without nasal polyps (CRSsNP)

22 (17.9%)

Chronic rhinosinusitis with nasal polyps (CRSwNP)

17 (13.8%)

Chronic spontaneous urticaria

1 (0.8%)

Chronic/recurrent respiratory infections

2 (1.6%)

Gastroesophageal reflux

16 (13.0%)

Hormonal disturbances

16 (13.0%)

Obesity

5 (4.1%)

Obstructive sleep apnea/sleep-disordered breathing

3 (2.4%)

Psychologic disease (anxiety, depression, behavioral disorders)

6 (4.9%)

Other

19 (15.4%)